Anticoagulation in heart failure: current status and future direction

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[3]  G. Filippatos,et al.  Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. , 2012, European heart journal.

[4]  S. Harder.  Renal Profiles of Anticoagulants , 2012, Journal of clinical pharmacology.

[5]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[6]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[7]  A. Banerjee,et al.  Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project , 2012, European Journal of Heart Failure.

[8]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[9]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[10]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[11]  Carlo Lombardi,et al.  Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study , 2011, Circulation. Heart failure.

[12]  F. Van de Werf,et al.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. , 2011, European heart journal.

[13]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[14]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[15]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[16]  R. Califf,et al.  2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[17]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[18]  G. Fonarow,et al.  Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. , 2011, The American journal of cardiology.

[19]  M. Gheorghiade,et al.  Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  C. O'connor,et al.  Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. , 2011, American heart journal.

[21]  C. Esmon,et al.  Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation , 2011, Thrombosis and Haemostasis.

[22]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[23]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[24]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[25]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  E. Antman,et al.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.

[27]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[28]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[29]  C. O'connor,et al.  Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.

[30]  K. Sliwa,et al.  The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. , 2010, European heart journal.

[31]  L. Køber,et al.  Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. , 2010, Journal of the American College of Cardiology.

[32]  David Garcia,et al.  The new oral anticoagulants. , 2010, Blood.

[33]  L. Køber,et al.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.

[34]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[35]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[36]  M. Mamas,et al.  Atrial fibrillation is under-recognized in chronic heart failure: insights from a heart failure cohort treated with cardiac resynchronization therapy. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[37]  G. Fonarow,et al.  Quality of care for atrial fibrillation among patients hospitalized for heart failure. , 2009, Journal of the American College of Cardiology.

[38]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[39]  B. Jug,et al.  Procoagulant state in heart failure with preserved left ventricular ejection fraction. , 2009, International heart journal.

[40]  O. C. Alebiosu,et al.  ACE-I induced angioedema: a case report and review of literature , 2009, Cases journal.

[41]  J. Tu,et al.  Anticoagulation in patients with heart failure. , 2009, Cardiovascular & hematological agents in medicinal chemistry.

[42]  C. O'connor,et al.  Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial , 2009, Circulation.

[43]  M. Gheorghiade,et al.  Acute heart failure syndromes , 2009, Journal of the American College of Cardiology.

[44]  M. Pfeffer,et al.  Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program , 2009, European journal of heart failure.

[45]  Jeroen J. Bax,et al.  Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. , 2009, Journal of the American College of Cardiology.

[46]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[47]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[48]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[49]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[50]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[51]  C. O'connor,et al.  Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. , 2008, Archives of internal medicine.

[52]  G. Fonarow,et al.  Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. , 2008, Journal of cardiac failure.

[53]  N. Mackman.  Triggers, targets and treatments for thrombosis , 2008, Nature.

[54]  I. Takeuchi,et al.  Prognostic significance of increased serum bilirubin levels coincident with cardiac decompensation in chronic heart failure. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[55]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[56]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[57]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[58]  V. Roger,et al.  The incidence of ischemic stroke in chronic heart failure: a meta-analysis. , 2007, Journal of cardiac failure.

[59]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[60]  J. Cleland,et al.  Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials , 2007, European journal of heart failure.

[61]  George A. Johnson,et al.  Risk of Thromboembolism in Heart Failure: An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2007, Circulation.

[62]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[63]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[64]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[65]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[66]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[67]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[68]  V. Roger,et al.  Ischemic stroke after heart failure: a community-based study. , 2006, American heart journal.

[69]  P. Toutouzas,et al.  Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study , 2006, European journal of heart failure.

[70]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[71]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[72]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[73]  K. Dickstein,et al.  Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. , 2005, The American journal of medicine.

[74]  S. Solomon,et al.  Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. , 2005, The New England journal of medicine.

[75]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[76]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[77]  P A Poole-Wilson,et al.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. , 2004, American heart journal.

[78]  K. Swedberg,et al.  Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. , 2004, European heart journal.

[79]  I. Piña.  Valsartan in acute myocardial infarction trial. , 2004, Current cardiology reports.

[80]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[81]  S. Jackson,et al.  Signaling events underlying thrombus formation , 2003, Journal of thrombosis and haemostasis : JTH.

[82]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[83]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[84]  C. O'connor,et al.  Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. , 2003, American heart journal.

[85]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[86]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[87]  G. Lip,et al.  Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm: Effects of Angiotensin-Converting Enzyme Inhibitor and &bgr;-Blocker Therapy , 2001, Circulation.

[88]  P. Poole‐Wilson,et al.  Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. , 2000, Circulation.

[89]  W. Weaver,et al.  Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. , 2000, Chest.

[90]  G. Lip,et al.  Does heart failure confer a hypercoagulable state? Virchow's triad revisited. , 1999, Journal of the American College of Cardiology.

[91]  W. Rand,et al.  Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[92]  B. Uretsky,et al.  Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? , 1997, Journal of the American College of Cardiology.

[93]  S. Goldstein,et al.  Effects of warfarin on markers of hypercoagulability in patients with heart failure. , 1997, American heart journal.

[94]  M. Domanski,et al.  Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. , 1997, Journal of the American College of Cardiology.

[95]  G. Lamas,et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.

[96]  P. Batin,et al.  The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. , 1995, European heart journal.

[97]  R. Virmani,et al.  Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. , 1995, Circulation.

[98]  T. Levine,et al.  Platelet function, thrombin and fibrinolytic activity in patients with heart failure. , 1993, European heart journal.

[99]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[100]  R D Fish,et al.  Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. , 1990, Circulation.

[101]  D. Mancini,et al.  Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. , 1985, Circulation.

[102]  A. Omran.  The epidemiologic transition. A theory of the epidemiology of population change. , 1971, The Milbank Memorial Fund quarterly.

[103]  K. Mahaffey,et al.  ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .

[104]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[105]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[106]  T. Lauer,et al.  [Pre-operative cardiac risk assessment]. , 2011, Deutsche medizinische Wochenschrift.

[107]  S. Homma,et al.  Stroke in heart failure: atrial fibrillation revisited? , 2010, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[108]  B. Gersh.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2010 .

[109]  M. Gheorghiade,et al.  Special cases in acute heart failure syndromes: atrial fibrillation and wide complex tachycardia. , 2009, Heart failure clinics.

[110]  R. McKelvie,et al.  Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. , 2006, The Canadian journal of cardiology.

[111]  A. Omran.  The epidemiologic transition: a theory of the epidemiology of population change. 1971. , 2005, The Milbank quarterly.

[112]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi , 2004, The Canadian journal of cardiology.

[113]  K. Mann,et al.  Thrombin formation. , 2003, Chest.

[114]  ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[115]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.